pSivida Corp Announces Third Quarter 2014 Financial Results Release Date and Conference Call Information

  pSivida Corp Announces Third Quarter 2014 Financial Results Release Date and
  Conference Call Information

Business Wire

WATERTOWN, Mass. -- May 2, 2014

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of
sustained release, drug delivery products for treating eye diseases, today
announced that its financial results for the third quarter of fiscal year 2014
will be released after the market close on Tuesday, May 13, 2014, followed the
same day by a conference call and live webcast scheduled for 4:30 p.m. ET.

The conference call may be accessed by dialing (877) 312-7507 from the U.S.
and Canada, or (631) 813-4828 from international locations. A live webcast
will be available on the Investor Relations section of the corporate website
at http://www.psivida.com.

A replay of the call will be available beginning May 13, 2014, at
approximately 7:30 p.m. ET and ending on May 20, 2014, at 11:59 p.m. ET. The
replay may be accessed by dialing (855) 859-2056 within the U.S. and Canada or
(404) 537-3406 from international locations, Conference ID Number: 40618782. A
replay of the webcast will also be available on the corporate website during
that time.

About pSivida Corp.

pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained
release, drug delivery products designed to deliver drugs at a controlled and
steady rate for months or years. pSivida is currently focused on treatment of
chronic diseases of the back of the eye utilizing its core technology systems,
Durasert™ and BioSilicon™, including Tethadur™. pSivida has instituted the
first of two planned pivotal Phase III clinical trials for its lead
development product, Medidur™, an injectable, sustained release micro-insert
for the treatment of posterior uveitis, a chronic back-of-the-eye disease.
ILUVIEN® for the treatment of chronic DME considered insufficiently responsive
to available therapies, which uses the same micro-insert as Medidur and is
licensed to Alimera Sciences, Inc., is marketed in the U.K. and Germany and
has also received marketing authorization in Austria, France, Portugal, and
Spain and is awaiting authorization in Italy. Alimera has filed for ten
additional EU country approvals through the Mutual Recognition Procedure.
Alimera is seeking approval of ILUVIEN in the U.S. An investigator-sponsored
clinical trial is ongoing for an injectable, bioerodible micro-insert to treat
glaucoma and ocular hypertension, a product candidate on which Pfizer Inc. has
an option. pSivida's FDA-approved Retisert®, licensed to Bausch & Lomb
Incorporated, provides long-term, sustained drug delivery to treat posterior
uveitis.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF
1995: Various statements made in this release are forward-looking, and are
inherently subject to risks, uncertainties and potentially inaccurate
assumptions. All statements that address activities, events or developments
that we intend, expect or believe may occur in the future are forward-looking
statements. The following are some of the factors that could cause actual
results to differ materially from the anticipated results or other
expectations expressed, anticipated or implied in our forward-looking
statements: uncertainties with respect to: ability of STA to achieve marketing
approvals, adequate pricing and reimbursement and market acceptance for and
successful commercialization of ILUVIEN for DME in Australia and New Zealand;
Alimera's ability to finance, achieve additional marketing approvals, obtain
adequate pricing and reimbursement for, successfully commercialize and achieve
market acceptance of, and generate revenues to pSivida from, ILUVIEN for DME
in the EU; Alimera's ability to obtain regulatory approval for, and if
approved, to finance, successfully commercialize and achieve market acceptance
of, and generate revenues to pSivida from, ILUVIEN for DME in the U.S.; the
ability to finance, complete and achieve a successful outcome for Phase III
trials for, and file and achieve marketing approvals for, Medidur for
posterior uveitis, including achieving acceptable risk-to-benefit and safety
profiles in light of the CRL for ILUVIEN; initiation, financing and success of
Latanoprost Product Phase II trials and any exercise by Pfizer of its option;
ability of Tethadur to successfully deliver proteins, peptides and other large
biologic molecules; ability to develop product candidates and products and
potential related collaborations; initiation and completion of clinical trials
and obtaining regulatory approval of product candidates; continued sales of
Retisert; adverse side effects; ability to attain profitability; ability to
obtain additional capital; further impairment of intangible assets;
fluctuations in operating results; decline in royalty income; ability to, and
to find partners to, develop and market products; termination of license
agreements; competition and other developments affecting sales of products;
market acceptance; protection of intellectual property and avoiding
intellectual property infringement; retention of key personnel; product
liability; consolidation in the pharmaceutical and biotechnology industries;
compliance with environmental laws; manufacturing risks; risks and costs of
international business operations; credit and financial market conditions;
legislative or regulatory changes; volatility of stock price; possible
dilution; absence of dividends; and other factors described in our filings
with the SEC. Given these uncertainties, readers are cautioned not to place
undue reliance on such forward-looking statements. Should known or unknown
risks materialize, or should underlying assumptions prove inaccurate, actual
results could differ materially from past results and those anticipated,
estimated or projected in the forward-looking statements. Our forward-looking
statements speak only as of the dates on which they are made. We do not
undertake any obligation to publicly update or revise our forward-looking
statements even if experience or future changes makes it clear that any
projected results expressed or implied in such statements will not be
realized.

Follow pSivida on social media:

Twitter: https://twitter.com/pSividaCorp

Facebook: https://www.facebook.com/pages/PSivida-Corp/544893792199562

LinkedIn: http://www.linkedin.com/company/psivida

Google+:
https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts

The President's Blog: http://www.thechairmansblog.com/paul-ashton

For more information on pSivida, visit www.psivida.com.

Contact:

Martin E. Janis & Company, Inc.
Beverly Jedynak, +1 312-943-1123
President
M: +1 773-350-5793
bjedynak@janispr.com
 
Press spacebar to pause and continue. Press esc to stop.